These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 31322481)

  • 1. Telomerase activation in small intestinal neuroendocrine tumours is associated with aberrant
    Fotouhi O; Ghaderi M; Wang N; Zedenius J; Kjellman M; Xu D; Juhlin CC; Larsson C
    Epigenetics; 2019 Dec; 14(12):1224-1233. PubMed ID: 31322481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA methylation of the TERT promoter and its impact on human cancer.
    Lee DD; Komosa M; Nunes NM; Tabori U
    Curr Opin Genet Dev; 2020 Feb; 60():17-24. PubMed ID: 32114294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TERT promoter hypermethylation is associated with poor prognosis in adrenocortical carcinoma.
    Svahn F; Paulsson JO; Stenman A; Fotouhi O; Mu N; Murtha TD; Korah R; Carling T; Bäckdahl M; Wang N; Juhlin CC; Larsson C
    Int J Mol Med; 2018 Sep; 42(3):1675-1683. PubMed ID: 29956721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Global hypomethylation and promoter methylation in small intestinal neuroendocrine tumors: an in vivo and in vitro study.
    Fotouhi O; Adel Fahmideh M; Kjellman M; Sulaiman L; Höög A; Zedenius J; Hashemi J; Larsson C
    Epigenetics; 2014 Jul; 9(7):987-97. PubMed ID: 24762809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recurrent TERT promoter mutations identified in a large-scale study of multiple tumour types are associated with increased TERT expression and telomerase activation.
    Huang DS; Wang Z; He XJ; Diplas BH; Yang R; Killela PJ; Meng Q; Ye ZY; Wang W; Jiang XT; Xu L; He XL; Zhao ZS; Xu WJ; Wang HJ; Ma YY; Xia YJ; Li L; Zhang RX; Jin T; Zhao ZK; Xu J; Yu S; Wu F; Liang J; Wang S; Jiao Y; Yan H; Tao HQ
    Eur J Cancer; 2015 May; 51(8):969-76. PubMed ID: 25843513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of human telomerase reverse transcriptase promoter methylation and transcription factor binding in differentiated thyroid cancer cell lines.
    Avin BA; Wang Y; Gilpatrick T; Workman RE; Lee I; Timp W; Umbricht CB; Zeiger MA
    Genes Chromosomes Cancer; 2019 Aug; 58(8):530-540. PubMed ID: 30664813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heterogeneity of telomerase reverse transcriptase mutation and expression, telomerase activity and telomere length across human cancer cell lines cultured in vitro.
    Dratwa M; Wysoczanska B; Turlej E; Anisiewicz A; Maciejewska M; Wietrzyk J; Bogunia-Kubik K
    Exp Cell Res; 2020 Nov; 396(1):112298. PubMed ID: 32971118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methylation of the TERT promoter and risk stratification of childhood brain tumours: an integrative genomic and molecular study.
    Castelo-Branco P; Choufani S; Mack S; Gallagher D; Zhang C; Lipman T; Zhukova N; Walker EJ; Martin D; Merino D; Wasserman JD; Elizabeth C; Alon N; Zhang L; Hovestadt V; Kool M; Jones DT; Zadeh G; Croul S; Hawkins C; Hitzler J; Wang JC; Baruchel S; Dirks PB; Malkin D; Pfister S; Taylor MD; Weksberg R; Tabori U
    Lancet Oncol; 2013 May; 14(6):534-42. PubMed ID: 23598174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TERT promoter mutations and telomeres during tumorigenesis.
    Lorbeer FK; Hockemeyer D
    Curr Opin Genet Dev; 2020 Feb; 60():56-62. PubMed ID: 32163830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Telomere elongation via alternative lengthening of telomeres (ALT) and telomerase activation in primary metastatic medulloblastoma of childhood.
    Minasi S; Baldi C; Pietsch T; Donofrio V; Pollo B; Antonelli M; Massimino M; Giangaspero F; Buttarelli FR
    J Neurooncol; 2019 May; 142(3):435-444. PubMed ID: 30830680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA hypermethylation within TERT promoter upregulates TERT expression in cancer.
    Lee DD; Leão R; Komosa M; Gallo M; Zhang CH; Lipman T; Remke M; Heidari A; Nunes NM; Apolónio JD; Price AJ; De Mello RA; Dias JS; Huntsman D; Hermanns T; Wild PJ; Vanner R; Zadeh G; Karamchandani J; Das S; Taylor MD; Hawkins CE; Wasserman JD; Figueiredo A; Hamilton RJ; Minden MD; Wani K; Diplas B; Yan H; Aldape K; Akbari MR; Danesh A; Pugh TJ; Dirks PB; Castelo-Branco P; Tabori U
    J Clin Invest; 2019 Jan; 129(1):223-229. PubMed ID: 30358567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Promoter hypermethylation of TERT is associated with hepatocellular carcinoma in the Han Chinese population.
    Zhang H; Weng X; Ye J; He L; Zhou D; Liu Y
    Clin Res Hepatol Gastroenterol; 2015 Oct; 39(5):600-9. PubMed ID: 25683523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential TERT promoter methylation and response to 5-aza-2'-deoxycytidine in acute myeloid leukemia cell lines: TERT expression, telomerase activity, telomere length, and cell death.
    Pettigrew KA; Armstrong RN; Colyer HA; Zhang SD; Rea IM; Jones RE; Baird DM; Mills KI
    Genes Chromosomes Cancer; 2012 Aug; 51(8):768-80. PubMed ID: 22517724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Telomerase activity, TERT expression, hTERT promoter alterations, and alternative lengthening of the telomeres (ALT) in meningiomas - a systematic review.
    Stögbauer L; Stummer W; Senner V; Brokinkel B
    Neurosurg Rev; 2020 Jun; 43(3):903-910. PubMed ID: 30788677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic and epigenetic background and protein expression profiles in relation to telomerase activation in medullary thyroid carcinoma.
    Wang N; Kjellin H; Sofiadis A; Fotouhi O; Juhlin CC; Bäckdahl M; Zedenius J; Xu D; Lehtiö J; Larsson C
    Oncotarget; 2016 Apr; 7(16):21332-46. PubMed ID: 26870890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Telomere length and TERT abnormalities in pituitary adenomas.
    Boresowicz J; Kober P; Rusetska N; Maksymowicz M; Goryca K; Kunicki J; Bonicki W; Bujko M
    Neuro Endocrinol Lett; 2018 Mar; 39(1):49-55. PubMed ID: 29803207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Telomere length assessment and molecular characterization of TERT gene promoter in periampullary carcinomas.
    Gregório C; Thakur S; Camara Rivero R; Márcia Dos Santos Machado S; Cuenin C; Carreira C; White V; Cree IA; Vukojevic K; Glavina Durdov M; Bersch Osvaldt A; Ashton-Prolla P; Herceg Z; Talukdar FR
    Gene; 2023 Jul; 873():147460. PubMed ID: 37150235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The TERT Promoter is Polycomb-Repressed in Neuroblastoma Cells with Long Telomeres.
    Graham MK; Xu B; Davis C; Meeker AK; Heaphy CM; Yegnasubramanian S; Dyer MA; Zeineldin M
    Cancer Res Commun; 2024 Jun; 4(6):1533-1547. PubMed ID: 38837897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms underlying the activation of TERT transcription and telomerase activity in human cancer: old actors and new players.
    Yuan X; Larsson C; Xu D
    Oncogene; 2019 Aug; 38(34):6172-6183. PubMed ID: 31285550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TERT promoter mutations and long telomere length predict poor survival and radiotherapy resistance in gliomas.
    Gao K; Li G; Qu Y; Wang M; Cui B; Ji M; Shi B; Hou P
    Oncotarget; 2016 Feb; 7(8):8712-25. PubMed ID: 26556853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.